BIOGEN INC
NASDAQ: BIIB (Biogen Inc.)
Last update: yesterday, 7:22PM200.81
-0.99 (-0.49%)
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - General (US) | Bullish | Mixed |
| Drug Manufacturers - General (Global) | Bullish | Mixed | |
| Stock | Biogen Inc. | Bearish | Bearish |
Stockmoo Score
|
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
| Investment Style | Mid Value |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 313.00 (Piper Sandler, 55.87%) | Buy |
| Median | 264.50 (31.72%) | |
| Low | 190.00 (Barclays, -5.38%) | Hold |
| Average | 256.63 (27.80%) | |
| Total | 5 Buy, 3 Hold | |
| Avg. Price @ Call | 209.72 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Needham | 04 Sep 2024 | 285.00 (41.93%) | Buy | 204.95 |
| 19 Aug 2024 | 285.00 (41.93%) | Buy | 206.06 | |
| Barclays | 02 Aug 2024 | 190.00 (-5.38%) | Hold | 205.66 |
| RBC Capital | 02 Aug 2024 | 292.00 (45.41%) | Buy | 205.66 |
| 27 Jun 2024 | 317.00 (57.86%) | Buy | 228.72 | |
| Scotiabank | 02 Aug 2024 | 244.00 (21.51%) | Buy | 205.66 |
| Wedbush | 02 Aug 2024 | 210.00 (4.58%) | Hold | 205.66 |
| Wells Fargo | 02 Aug 2024 | 225.00 (12.05%) | Hold | 205.66 |
| Baird | 29 Jul 2024 | 294.00 (46.41%) | Buy | 214.43 |
| Piper Sandler | 12 Jul 2024 | 313.00 (55.87%) | Buy | 230.06 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |